Allergic contact dermatitis due to cosmetics
Methodology & AI Transparency ⓘ
Allergic contact dermatitis due to cosmetics Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as L23.2, Allergic contact dermatitis due to cosmetics falls under Skin & Dermatology management, where or targeted biologics [Allergic contact dermatitis due to cosmetics L23.2] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Allergic contact dermatitis due to cosmetics uses ICD-10 L23.2 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Allergic contact dermatitis due to cosmetics (L23.2) utilizes or targeted biologics [Allergic contact dermatitis due to cosmetics L23.2].
- 4 Top reported side effects / signs: Follow-up benchmark in Allergic contact dermatitis due to cosmetics: maintaining Affected Body Surface in Allergic contact dermatitis due to cosmetics (L23.2: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (L23.2).
Ask our AI Specialists anything about Allergic contact dermatitis due to cosmetics
What Is Allergic contact dermatitis due to cosmetics?
Designated in federal medical registries as L23.2, Allergic contact dermatitis due to cosmetics falls under Skin & Dermatology management, where or targeted biologics [Allergic contact dermatitis due to cosmetics L23.2] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Allergic contact dermatitis due to cosmetics (L23.2) features cutaneous immune skewing in Allergic contact dermatitis due to cosmetics (L23.2: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against Fasting Lipids & in Allergic contact dermatitis due to cosmetics (L23.2: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Allergic contact dermatitis due to cosmetics (L23.2): recurrent flares triggered in Allergic contact dermatitis due to cosmetics (L23.2: by UV exposure,)
- • Secondary Allergic contact dermatitis due to cosmetics clinical sign: persistent erythematous plaques, in Allergic contact dermatitis due to cosmetics (L23.2: scaly patches, pruritic)
- • Symptom flares in Allergic contact dermatitis due to cosmetics correlating with Affected Body Surface in Allergic contact dermatitis due to cosmetics (L23.2: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L23.2)
- • Functional skin & dermatology impact requiring or targeted biologics [Allergic contact dermatitis due to cosmetics L23.2] evaluation (L23.2)
Allergic contact dermatitis due to cosmetics Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L23.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Allergic contact dermatitis due to cosmetics (L23.2: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L23.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Allergic contact dermatitis due to cosmetics (L23.2: ALT (if systemic) | Within baseline reference limits (L23.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Allergic contact dermatitis due to cosmetics (L23.2: & hs-CRP) | 25(OH)D 40–65 ng/mL (L23.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Allergic contact dermatitis due to cosmetics
Treatment selection for Allergic contact dermatitis due to cosmetics depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Allergic contact dermatitis due to cosmetics)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Gold-standard blind, compared against a dummy pill (placebo) Trial of the: What a 486-Participant Study Found Here, 0.15% AZE significantly improved the overall rTNSS compared with placebo over the 28-day study period. International archives of allergy and immunology • 2025-01-15 • Phase III Randomized Trial | N = 486 | 93/100 | PMID 39647474 ↗ |
| New Insights on Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With: What a 639-Participant Study Found Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. Contact dermatitis • 2026-07-15 • Phase III Randomized Trial | N = 639 | 93/100 | PMID 41775339 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III study of Phlai capsules in the treatment of allergic rhinitis: A Phlai was safe. Asian Pacific journal of allergy and immunology • 2026-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37302097 ↗ |
| Can This Approach Help? Inside the Latest Research on SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. Allergy • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41064908 ↗ |
| Can This Approach Help? Inside the Latest Research on Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post TAA produced effective and prolonged improvement of PAR symptoms over a 4-week treatment period. International archives of allergy and immunology • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34535609 ↗ |
Allergic contact dermatitis due to cosmetics Patient Community & “People Like Me” Threads
Filter Allergic contact dermatitis due to cosmetics community threads and patient logs by age, biological sex, dosage, and treatment duration.